Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PAVmed Inc. (PAVM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed, commercial-stage medical technology company. Through these documents, investors can review how PAVmed reports its operations in the medical device, diagnostics, and digital health sectors, along with detailed financial information and corporate actions.
Current reports on Form 8-K include items such as press releases announcing quarterly financial results and business updates. For example, PAVmed has filed an 8-K to furnish a press release covering financial results for the quarter ended September 30, 2025 and a related business update. These filings give context on revenue, operating expenses, non-GAAP measures such as EBITDA and adjusted loss, and commentary on the performance of subsidiaries like Lucid Diagnostics Inc. and Veris Health Inc.
Proxy materials such as the definitive proxy statement on Schedule 14A provide insight into corporate governance and stockholder proposals. PAVmed’s definitive proxy statement for a special meeting of stockholders describes proposals to approve a reverse stock split within a specified ratio range and a reduction in authorized common stock, along with the reasons for these actions, including efforts to meet Nasdaq’s minimum bid price requirement.
On this page, users can also monitor periodic reports such as Forms 10-Q and 10-K (when available), which contain comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures. These filings are important for understanding PAVmed’s financial condition, capital structure, and its activities in medical technology development, commercialization, and digital health.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping readers quickly identify information on topics such as quarterly performance, non-GAAP reconciliations, reverse stock split mechanics, and subsidiary operations. The platform also surfaces real-time updates from EDGAR, so new PAVM filings appear promptly as they are submitted.
Aklog Lishan reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. Chairman and CEO Lishan Aklog received a grant of 350,000 shares of restricted common stock, awarded at $0.00 per share as equity compensation. The restricted stock was granted under PAVmed's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The award is subject to forfeiture if the required service period is not completed, tying the grant to long-term leadership retention. Following this grant, Dr. Aklog directly holds 357,614 shares of common stock, with additional indirect interests reported through family members and investment entities.
PAVmed Inc. Schedule 13G reports that the Craig Kallman 2015 Living Trust and Craig Kallman together beneficially own 384,616 shares of PAVmed common stock. The filing states this equals 6.0% of the class, based on 6,383,089 shares outstanding as of March 27, 2026.
The Trust holds sole voting and sole dispositive power over the 384,616 shares. The Reporting Persons filed a Joint Filing Agreement and note Mr. Kallman controls the Trust.
MCGRATH DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that President and CFO Dennis M. McGrath received a grant of 180,000 shares of restricted common stock on April 2, 2026. The award was made under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
The restricted stock carries a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, McGrath directly holds 186,695 shares of PAVmed common stock.
Glennon Michael J reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Michael J. Glennon reported an award of 13,930 shares of restricted common stock as equity compensation. The shares were granted at no cash cost to him under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and have a single vesting date of May 20, 2029. The restricted stock is subject to forfeiture if he does not complete the required service period. Following this grant, Glennon directly holds 21,653 shares of PAVmed common stock.
Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Timothy E. Baxter received a grant of 13,930 shares of restricted common stock as equity compensation. These shares vest on May 20, 2029 and may be forfeited if he does not complete the required service period. Following this award, he directly holds 21,097 common shares.
White Debra reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Debra White received a grant of 13,930 shares of restricted common stock as compensation. The award was granted at $0.00 per share under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed. Following this grant, White directly holds 21,097 shares of PAVmed common stock.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Ronald M. Sparks received a grant of 13,930 shares of common stock as restricted stock under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. The award has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Sparks directly holds 21,097 shares of PAVmed common stock.
Agrawal Sundeep reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Sundeep Agrawal received a grant of 13,930 shares of restricted Common Stock as equity compensation. The award was granted at no cash purchase price and increases his direct holdings to 19,337 shares after the transaction.
The restricted stock was issued under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if he does not complete the required service period, tying the award to long-term board service.
PAVmed Inc. reports that Tasso Partners, LLC and Dana Carrera beneficially own 912,996 and 914,246 shares respectively, representing 14.3% of outstanding common stock. The percentage is calculated using 6,383,089 shares outstanding as of March 27, 2026, per the annual report on Form 10-K.
The filing states Ms. Carrera controls Tasso Partners through Tasso Capital, LLC and that the Reporting Persons filed this Amendment No. 1 jointly under a Joint Filing Agreement.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. granted its General Counsel, Michael Adam Gordon, 110,000 shares of restricted common stock as equity compensation. The shares were granted at no cash cost and bring his direct holdings to 115,000 shares. The award vests on May 20, 2029 and is subject to forfeiture if he does not complete the required service period, making this a long-term retention incentive rather than an open-market purchase.